Trials
3 active
8 in total · 2 in the EU
What this is
- How it works
- CD40 ligand (CD40L) antibody
- How it’s given
- “AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent”In the company’s words, NCT06126380 on ClinicalTrials.gov
- Tested for
- Kidney Transplant Rejection (2 trials), Prevention of Rejection in Kidney Transplant
- Main trialPhase 3
- “This study will evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult participants undergoing first kidney transplantation.”In the company’s words, NCT07835581 on ClinicalTrials.gov
- Other names
- AT-1501
Other drugs for Kidney Transplant Rejection
- Migalastat HClAmicus Therapeutics · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
- SymvessHumacyte, Inc. · Phase 3
- RoxadustatAstellas · Phase 3
- RetatrutideEli Lilly · Phase 3
- ClazakizumabCSL Behring · Phase 2/3
Coming up3
- Jan 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Mar 2029Phase 3 trial completes · ClinicalTrials.gov
- Dec 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Mar 2029 | Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation | |
| Phase 2Enrolling by invitation | Dec 2029 | Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients | |
| Phase 1/2Recruiting | Jan 2027 | Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant | |
| Phase 2Completed | 24 Mar 2022 | Multiple Doses of AT-1501-A201 in Adults With ALS | |
| Phase 2Terminated | 31 Jul 2023 | Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) | |
| Phase 2Withdrawn | Jun 2024 | Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation | |
| Phase 2Completed | 11 Sep 2025 | Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation | |
| Phase 1/2Withdrawn | Aug 2024 | Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026